比较顺铂/S-1与多西他赛/顺铂/S-1两种及四周期新辅助化疗治疗局部晚期胃癌的随机二乘二析因II期试验早期结果
本随机二乘二析因II期试验纳入132例M0且T4或T3(交界型或硬癌型)胃癌患者,随机接受两或四周期顺铂/S-1(CS)或多西他赛/顺铂/S-1(DCS)新辅助化疗,主要终点为3年总生存。早期结果显示CS组病理缓解率19.4% vs DCS组15.4%,R0切除率CS组72.7% vs DCS组81.8%,两周期组病理缓解率15.6% vs 四周期组19.0%,R0切除率两周期组80.3% vs 四周期组74.2%,未观察到治疗相关死亡。作者结论不支持以含紫杉类三药方案替代两药方案,也不支持超过两周期的新辅助化疗作为有吸引力的试验组候选方案。
要点
- CS组与DCS组病理缓解率分别为19.4%与15.4%,两周期组与四周期组分别为15.6%与19.0%。
- CS组与DCS组R0切除率分别为72.7%与81.8%,两周期组与四周期组分别为80.3%与74.2%。
- 主要3/4级血液学毒性:白细胞减少CS组14.1% vs DCS组26.2%,中性粒细胞减少CS组29.7% vs DCS组47.7%,未观察到治疗相关死亡。
核心结论
- 作者结论认为结果不支持以含紫杉类三药方案替代两药方案,也不支持超过两周期的新辅助化疗作为有吸引力的试验组候选方案。
研究设计与样本
- 随机二乘二析因II期试验,2011年10月至2014年9月纳入132例M0且T4或T3(交界型或硬癌型)胃癌患者,随机分配至CS组(n=66,其中两周期33例、四周期33例)或DCS组(n=66,其中两周期33例、四周期33例)。
- CS方案:顺铂60 mg/m2第8天,S-1 80 mg/m2用21天休1周;DCS方案:多西他赛40 mg/m2第1天,顺铂60 mg/m2第1天,S-1 80 mg/m2用14天休2周;新辅助化疗后行D2胃切除术及辅助S-1化疗1年。
- 主要终点为3年总生存。
主要发现
- 主要3/4级血液学毒性(CS组/DCS组):白细胞减少14.1%/26.2%,中性粒细胞减少29.7%/47.7%,贫血14.1%/12.3%,血小板减少3.1%/1.5%。
- 病理缓解(完全缓解或残留癌<10%)率:CS组19.4% vs DCS组15.4%;两周期组15.6% vs 四周期组19.0%。
- R0切除率:CS组72.7% vs DCS组81.8%;两周期组80.3% vs 四周期组74.2%。
- 未观察到治疗相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy (NAC) is a promising method of improving the survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) are both effective against metastatic gastric cancer. This report clarified the impact of these regimens on early endpoints, including the pathological responses, chemotherapy-related toxicities, and surgical results. METHODS: Patients with M0 and either T4 or T3 in case of junctional cancer or scirrhous type received two or four courses of cisplatin (60 mg/m2 at day 8)/S-1 (80 mg/m2 for 21 days with 1 week rest) or docetaxel (40 mg/m2 at day 1)/cisplatin (60 mg/m2 at day 1)/S-1 (80 mg/m2 for 14 days with 2 weeks rest) as NAC. Patients then underwent D2 gastrectomy and adjuvant S-1 chemotherapy for 1 year. The primary endpoint was the 3-year overall survival. RESULTS: Between October 2011 and September 2014, 132 patients were assigned to receive CS (n = 66; 33 in 2 courses and 33 in 4 courses) or DCS (n = 66; 33 in 2 courses and 33 in 4 courses). The respective major grade 3 or 4 hematological toxicities (CS/DCS) were leukocytopenia (14.1%/26.2%), neutropenia (29.7%/47.7%), anemia (14.1%/12.3%), and platelet reduction (3.1%/1.5%). The rate of pathological response, defined as a complete response or < 10% residual cancer remaining, was 19.4% in the CS group and 15.4% in the DCS group, and 15.6% in the two-course group and 19.0% in the 4-course group. The R0 resection rate was 72.7% in the CS group and 81.8% in the DCS group and 80.3% in the two-course group and the 74.2% in the four-course group. No treatment-related deaths were observed. CONCLUSIONS: Our results do not support three-drug therapy with a taxane over two-drug therapy, or any further treatment beyond two cycles as an attractive candidate for the test arm of NAC.
引用
- Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017. PMID: 28486692. doi:10.1093/annonc/mdx236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。